Lv0
0 积分 2026-05-14 加入
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
2小时前
已完结
First-line treatment for advanced NSCLC in older patients and those with poor performance status
2小时前
已完结
Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
4个月前
已完结
Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
4个月前
已完结
Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study
5个月前
已完结
Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study
5个月前
已关闭
Development of a machine learning-based prognostic model for survival prediction in patients with lung cancer brain metastases using multicenter clinical data
5个月前
已完结
皖公网安备34019202002308
